Literature DB >> 15043812

Multiple classes of MSL binding sites target dosage compensation to the X chromosome of Drosophila.

Hyangyee Oh1, James R Bone, Mitzi I Kuroda.   

Abstract

MSL complexes bind hundreds of sites along the single male X chromosome to achieve dosage compensation in Drosophila. Previously, we proposed that approximately 35 "high-affinity" or "chromatin entry" sites (CES) might nucleate spreading of MSL complexes in cis to paint the X chromosome. This was based on analysis of the first characterized sites roX1 and roX2. roX transgenes attract MSL complex to autosomal locations where it can spread long distances into flanking chromatin. roX1 and roX2 also produce noncoding RNA components of the complex. Here we identify a third site from the 18D10 region of the X chromosome. Like roX genes, 18D binds full and partial MSL complexes in vivo and encompasses a male-specific DNase I hypersensitive site (DHS). Unlike roX genes, the 510 bp 18D site is apparently not transcribed and shows high affinity for MSL complex and spreading only as a multimer. While mapping 18D, we discovered MSL binding to X cosmids that do not carry one of the approximately 35 high-affinity sites. Based on additional analyses of chromosomal transpositions, we conclude that spreading in cis from the roX genes or the approximately 35 originally proposed "entry sites" cannot be the sole mechanism for MSL targeting to the X chromosome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15043812     DOI: 10.1016/j.cub.2004.03.004

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  45 in total

Review 1.  Dosage compensation, the origin and the afterlife of sex chromosomes.

Authors:  Jan Larsson; Victoria H Meller
Journal:  Chromosome Res       Date:  2006       Impact factor: 5.239

2.  The MLE subunit of the Drosophila MSL complex uses its ATPase activity for dosage compensation and its helicase activity for targeting.

Authors:  Rosa Morra; Edwin R Smith; Ruth Yokoyama; John C Lucchesi
Journal:  Mol Cell Biol       Date:  2007-11-26       Impact factor: 4.272

3.  High-resolution ChIP-chip analysis reveals that the Drosophila MSL complex selectively identifies active genes on the male X chromosome.

Authors:  Artyom A Alekseyenko; Erica Larschan; Weil R Lai; Peter J Park; Mitzi I Kuroda
Journal:  Genes Dev       Date:  2006-03-17       Impact factor: 11.361

4.  Cotranscriptional recruitment of the dosage compensation complex to X-linked target genes.

Authors:  Jop Kind; Asifa Akhtar
Journal:  Genes Dev       Date:  2007-08-15       Impact factor: 11.361

5.  Studies on the short range spreading of the male specific lethal (MSL) complex on the X chromosome in Drosophila.

Authors:  X Sun; J A Birchler
Journal:  Cytogenet Genome Res       Date:  2009-05-05       Impact factor: 1.636

6.  Two classes of dosage compensation complex binding elements along Caenorhabditis elegans X chromosomes.

Authors:  Timothy A Blauwkamp; Gyorgyi Csankovszki
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

Review 7.  Drosophila dosage compensation: a complex voyage to the X chromosome.

Authors:  Marnie E Gelbart; Mitzi I Kuroda
Journal:  Development       Date:  2009-05       Impact factor: 6.868

Review 8.  Dosage compensation in Drosophila.

Authors:  John C Lucchesi; Mitzi I Kuroda
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-05-01       Impact factor: 10.005

9.  Species-specific positive selection of the male-specific lethal complex that participates in dosage compensation in Drosophila.

Authors:  Monica A Rodriguez; Danielle Vermaak; Joshua J Bayes; Harmit S Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-18       Impact factor: 11.205

10.  The Drosophila dosage compensation complex binds to polytene chromosomes independently of developmental changes in transcription.

Authors:  I V Kotlikova; O V Demakova; V F Semeshin; V V Shloma; L V Boldyreva; M I Kuroda; I F Zhimulev
Journal:  Genetics       Date:  2005-08-03       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.